Clinical trials: Mielodysplasic Syndrome
Acute Leukemia, Mielodysplasic Syndrome
Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning
Because the anti-leukemic activity of busulfan, this dug is largely used in graft conditioning but in elderly and/or cormobid patienth an excess of toxicity is observed.
- Conditions
- Acute Leukemia, Mielodysplasic Syndrome, Myeloproliferative Neoplasm
- Trial name
- BUSEQ (NCT04451200)
- Testing
- Busulfan Injection
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes